Aptima® CMV Quant Assay

    FDA-Approved solution to reliably and efficiently deliver actionable viral load insights to post-transplant patients and their care teams.

      Overview

      Documents

      Package Inserts

      CMV and Viral Load Monitoring

      Cytomegalovirus (CMV) infection is a common complication that affects organ transplant patients. CMV, a member of the herpes virus family, establishes a lifelong latent infection that is generally asymptomatic. However, in immunocompromised patients, such as transplant recipients, reactivation of latent CMV is often life-threatening. Guidelines recommend regular monitoring of CMV viral load as an aid for diagnosis of CMV infections and monitoring response to treatment.1, 2

      The Aptima CMV Quant assay intended use is to:

      Monitor Viral Load

      Assess viral response to treatment with
      serial DNA measurements in patients receiving
      anti-CMV therapy.

      Inform Care

      Aid in the management of solid-organ transplant patients and hematopoietic stem cell transplant patients.

      “We have a legacy of innovation in viral load testing, and our Aptima CMV Quant assay is the first in a series of quantitative assays to support patient care following transplant surgery. We’re committed to providing our laboratory partners with superior solutions that improve workflow efficiency and address the challenges faced by today’s molecular lab.”
      Kevin Thornal, Group President, Global Diagnostic Solutions

        Excellent performance for high-quality results

        Deliver accurate, consistent, and clinically actionable viral load insights with our extensively-validated quantitative CMV assay.

        Sensitivity:  

        • LoD – 40.7 IU/mL plasma
        • LLoQ – 53 IU/mL plasma
           

        Specificity:

        • 99.7% plasma

        Efficient workflow for a productive lab

        Improved laboratory workflow with the Aptima CMV Quant Assay on the Panther® system.

        Fully automated with random access and LIS integration 

        • Reduce hands-on time
        • Time-to-result in ~2h 40 min
           

        1-touch tube standardization

        • Direct loading of plasma primary tube (500 uL)
        • No manual sample extraction required for less operator error
        • No individual tubes transfers between platforms or between labs
           

        Run Aptima CMV Quant assay in parallel with our core viral assays: Aptima® HIV-1 Quant Dx, Aptima® HCV Quant Dx, and Aptima® HBV Quant assays

        The highest degree of standardization

        Ensure multisite accurate performance to reliably monitor transplant patients’ viral load trends over time and across geographies with the Aptima CMV Quant assay.

        Guideline driven

        • Completely aligns with the 1st WHO International Standard.
           

        Consistent Reproducibility

        • Uses the same panel of samples to evaluate across multiple operators, instruments and locations to deliver consistent results across all variables.

        Claim

        Quant

        LoD

        40.7 IU/mL plasma

        LLoQ

        53 IU/mL plasma

        Methodology

        RT-TMA

        Verified Sample Type

        Plasma (EDTA, PPT)

        One reliable partner

        Trust in a single lab partner to maximize your lab’s operational efficiencies.

        Expanding menu

        With 19 FDA-approved assays and an ever growing menu with 7 assays in development, you can now integrate and consolidate transplant and core viral load assays on a single high-throughput system.

        Consolidation efficiencies

        Help reduce LIS connection costs, streamline tech training, and drive cost efficiencies in lab purchasing and resource management with consolidation of platforms.

        Excellent customer service

        Our award-winning customer service means you are one call away from a large team that supports all your reagent needs.

        Disclaimers:
        * The Aptima SARS-CoV-2, Aptima Zika Virus, Aptima SARS-CoV-2/Flu and Panther Fusion SARS-CoV-2 assays have not been FDA cleared or approved: These tests have been authorized by FDA under an EUA for use by authorized laboratories; The Aptima and Panther Fusion SARS-CoV-2 assays have been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens; The Aptima Zika Virus assay has been authorized only for the detection of nucleic acid from Zika virus, not for any other viruses or pathogens; The Aptima SARS-CoV-2/Flu assay  has been authorized only for the simultaneous qualitative detection and differentiation of nucleic acid from SARS-CoV-2, influenza A virus, influenza B virus, and not for any other viruses or pathogens. The Aptima SARS-CoV-2, Panther Fusion SARS-CoV-2, and Aptima SARS-CoV-2/Flu assays are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. The Aptima Zika assay is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection of Zika virus and/or diagnosis of Zika virus infection under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

        † In development and not for sale.

        References:

        1. Kotton, Camille N; Kumar, Deepali; Caliendo, Angela M; Huprikar, Shirish; Chou, Sunwen; Danziger-Isakov, Lara; Humar, Atul (2018). The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation. Transplantation, 102(6):900-931. 2. Razonable AA, Humar A. Cytomegalovirus in solid organ transplant recipients-Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. (2019) 33(9).

         

        Explore the data

        Learn more about the Aptima® CMV assay on the Panther® system.

        Aptima® CMV Quant Assay

        Accurate results for a successful patient monitoring and treatment strategy.

        Placeholder image

          Cytomegalovirus (CMV) is member of Herpesviridae Family and is an enveloped, double-stranded DNA virus. Globally, 40-60% of the adult population have had prior CMV infection and could exceed 90% in some patient populations.1 CMV is usually asymptomatic in healthy individuals but remains in the body in a latent state. For patients undergoing solid organ or hematopoietic stem cell transplant, CMV infection and reactivation can lead to serious complications. If left untreated, CMV infection can lead to severe disease, transplant rejection, and death.

          The Third International Consensus Guidelines on the Management of Cytomegalovirus recommends quantitative nucleic acid amplification testing (QNAT) as the preferred method of monitoring CMV infection in patients post transplantation.2 This use of QNAT assays calibrated to the World Health Organization (WHO) International Standard, like the Aptima CMV Quant assay, decreases variability in results resulting.

          1.Cedeno-Mendoza R, Vanchhawng Pedroza, L. What is the prevalence of cytomegalovirus (CMV) infection? [Internet]. Medscape; 2021. [cited 2021 Aug 31]. Available from: https://www.medscape.com/answers/215702-99933/what-is-the-prevalence-of-cytomegalovirus-cmv-infection. 2. Kotton CN, Kumar D, Caliendo AM, Huprikar S, Chou S, Danziger-Isakov L, et al. The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation. Transplantation. 2018;102(6):900-931.
          CE + 1434         EC REP logo     Hologic BV, Da Vincilaan 5, 1930 Zaventem, Belgium.